For Clinicians | Bacterial vs Viral Infection

For Clinicians | Bacterial vs Viral Infection

When Antibiotics Actually Help, and When to Wait

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member

How do you know if an infection is bacterial or viral?

Every one of us has had this visit. A patient who feels awful, certain it’s bacterial, already asking for the antibiotic by name. And an exam that, if we’re being straight about it, could go either way.

Here’s the really hard part: signs alone often can’t separate bacteria from viral. Not reliably. And the labs don’t bail us out the way we’d like, either. CRP, procalcitonin, a white count, even all three together nudge the probability without handing over a clean, clear, simple verdict. Patients lean hard on yellow mucus, a single fever, the ‘it’s been five days’ clock. None of those reliably tell you a thing. They feel diagnostic but darn it, they aren’t. And they drive a whole lot of prescriptions that never had a real shot at helping.

So this isn’t going to be a bacterial-versus-viral checklist. You’ve already got one. What’s actually hard, and what actually changes outcomes, is the layer underneath: holding that uncertainty well in front of a patient who came in wanting a clean answer and a prescription.

So today we’re walking the three moves that live in this gray space. What genuinely raises suspicion. When waiting is the right call, and why the evidence backs it instead of treating it as a cop-out. And the narrow, specific place a standby antibiotic actually belongs. None of it skips the clinical judgment. All of it just makes that judgment easier to hold.

The real skill is holding the uncertainty

We were trained to find the answer. Name the bug, match the drug, move on. That reflex gets drilled in from our first courses of our advanced degrees. So when the answer won’t come, when the exam and the labs both just shrug at us, it feels like a failure of skill rather than a feature of the disease. It isn’t. Most everyday infections live in that gray, and the actual skill is staying steady inside it instead of forcing a resolution that the evidence won’t support.

And that brings us to the typical forced resolution. It’s the antibiotic prescription. We all know the pull: the patient expects it, the visit is already running long, and a script is the fastest way to send everyone home feeling like something happened that was worth their copay. Nobody sets out to over-prescribe. It’s just that “let’s treat it to be safe” is the path of least resistance, and patients have learned to expect it, which makes the next clinician’s “no” land like somebody’s holding out on them.

Holding the uncertainty well is the alternative, and it’s a real clinical act, not a soft one. It means saying out loud the thing we’d rather not: I can’t tell you for certain today whether this is bacterial, and here’s why that’s actually okay. It means giving the patient a plan for both branches instead of a pill for one. If this is viral, here’s the course it should run and the exact point where you come back. If it turns, here’s what we do then. That isn’t doing nothing. That’s doing the harder thing.

Everything that follows sits on that footing. The three moves aren’t a way around the uncertainty. They’re how you hold onto it without dropping it on the patient or papering over it with a drug.

What actually raises suspicion for a bacterial infection?

Let us start with the caveat that matters: almost everything here is probabilistic. These aren’t rule-in tests, they’re the findings that move the needle just enough to act, and they look different in every category. Here’s where the suspicion is actually earned in the infections we see most.

UTI: the symptom is the diagnosis. A positive dipstick is not a UTI. Bacteriuria without attributable symptoms (dysuria, urgency, frequency, suprapubic pain) is asymptomatic bacteriuria, and IDSA recommends against treating it in almost everyone outside pregnancy and patients headed for a urologic procedure.¹ This is the cleanest version of the whole article’s premise: a positive test is not an infection. The patient with real symptoms and a positive dip is a different person than the patient with a positive dip and nothing else, and only one of them has a UTI.

Skin and soft tissue: here you actually do get to trust your eyes, mostly. Cellulitis announces itself with spreading warmth, redness, and tenderness. The hard call usually isn’t “is it bacterial,” it’s “how sick is this person,” and that’s where the red flags matter more than the label:

• Pain out of proportion to what you’re seeing (think necrotizing, and move fast)
• Rapid progression you can track by the hour
• Systemic toxicity: fever, hypotension, a sustained tachycardia, two or more SIRS criteria

Those move a patient from “treat and recheck” to “this needs a higher level of care right now.” The flip side is just as useful: uncomplicated cellulitis should turn the corner within 24 to 48 hours of starting therapy.² If it doesn’t, the next question isn’t “stronger antibiotic,” it’s “wrong diagnosis, or something deeper.”

Strep throat: this is what Centor is for. Tonsillar exudate, tender anterior cervical nodes, absence of cough, a history of fever. Fewer than three of those and most patients need neither a swab nor a script.³ The reflex to test and treat every sore throat is exactly the low-value move the score exists to stop.

Respiratory (the big one): this is where suspicion should be hardest to earn, not easiest. Most acute sinusitis, and essentially all acute bronchitis, is viral.⁴ Antibiotics in sinusitis are for genuinely bacterial features or persistence past an observation window, not for the calendar and not for the color of what’s in the tissue. Bronchitis doesn’t get an antibiotic unless you’re actually worried about pneumonia. Cold, flu, COVID: never. This is the category that generates the most “I’m sure it’s bacterial” visits and the fewest infections that actually are.

The thread through all four: suspicion is local and specific, not a global sense that someone seems sick enough to deserve a drug. When the findings genuinely line up, you treat. When they don’t, you’ve got a second move that’s every bit as evidence-based as the first.

When is it safe to wait?

Now before you start to stress seeing this section title take a deep breath. This is the move that feels wrong until you look at the data, and then it feels obvious. Watchful waiting isn’t the absence of a plan. Done right, it is the plan, and it has a real evidence base under it.

The cleanest version is the back-up, or delayed, prescription: the patient leaves with a script in hand (or one you’ll send if needed), plus clear instructions to fill it only if they aren’t improving by a set point or they cross a specific line you’ve drawn. The Cochrane review on delayed prescribing for respiratory infections found it cut antibiotic use sharply versus prescribing immediately, with no increase in complications and patient satisfaction that holds up.⁵ The individual-patient-data meta-analysis landed in the same place: for most symptom outcomes, delayed performs about as well as immediate, and far better on the number that matters for stewardship, which is how many people actually swallow an antibiotic they never needed.⁶

What makes it work is the part we can’t skip: the return plan. Delayed prescribing is safe because the patient knows exactly what they’re watching for and exactly when to come back. Take that away and it’s just a slower prescription. And there’s a real caveat to sit with: at least one analysis tied delayed prescribing in upper-respiratory infection to a higher risk of hospital admission, a reminder that this is a tool for the borderline, self-limited case, not a blanket policy you run on everyone who walks in.⁷ The sicker the patient and the higher the stakes, the less this belongs.

Used in its lane, though, the back-up prescription is one of the most useful tools we have for the gray space. It tells the patient the truth: I don’t think you need this today, I could be wrong, and here’s how we’ll both know. It treats them as a partner in the uncertainty instead of resolving it on their behalf with a drug they probably don’t need.

And notice what it actually is, underneath. It’s a clinician deciding, ahead of time, that an antibiotic is warranted only if a specific condition is met, then putting the medication within reach for that exact moment. Hold that thought. It’s the whole idea behind the third move.

So what IS it for, down there? A short, specific list:

• Giardiasis
• Amebiasis (intestinal, and liver abscess), followed by an intraluminal agent
• C. diff, with the asterisk from a minute ago: not first-line anymore
• Intra-abdominal infection, where it’s always paired with a gram-negative agent, never flying solo

Notice what’s missing. Undifferentiated “food poisoning.” Routine traveler’s diarrhea, too. CDC’s Yellow Book puts azithromycin first-line and fluoroquinolones second for traveler’s diarrhea and metronidazole isn’t on that ladder at all. It’s reserved for Giardia, and even there it’s one option alongside tinidazole and nitazoxanide.⁸ It’s a specialist, not a generalist. Reach for it when you’ve got an anaerobe or a protozoan in your sights…not when a patient tells you their stomach is “off.”

And that narrowness, the very thing that makes it the wrong empiric pick for a vague gut complaint, is exactly why metronidazole can’t be the only gut drug in any kit worth building. Which is right where we’re headed next.

Where does a standby antibiotic actually fit?

So far, the gray space has had a clinician standing in it. Someone to examine, to decide, to be called back in 48 hours. Almost everything above assumes that person is reachable. Pull that assumption out, and the picture changes.

Think about the patient who is genuinely going to need an antibiotic and genuinely can’t get to anyone when the moment arrives. The recurrent-UTI patient with a documented workup and a clinician-set plan, who feels the exact symptoms she’s felt a dozen times, on a weekend, six hours from the nearest clinic. The traveler with a tick bite deep in the backcountry. Traveler’s diarrhea somewhere “go see someone” isn’t a real option for days. For those people, access is the binding constraint, not the diagnosis. And that is the only place a standby antibiotic earns its keep.

Notice it’s the same structure as the back-up prescription from a minute ago: a clinician deciding, in advance, that a drug is warranted only if a specific, recognizable condition is met, then putting it within reach for that moment. The back-up script solves for time. A standby kit solves for access. Same logic, same discipline, same requirement that a clinician drew the line first.

Which is exactly why that line has to be drawn narrowly, and why we’re loud about where it isn’t. A standby antibiotic is defensible only when two things are both true: self-recognition is reliable, and access is the real barrier. That points at a short list of access-tier drugs and clearly bounded indications: amoxicillin-clavulanate, doxycycline, metronidazole, for the worked-up recurrent UTI, the tick exposure, the giardiasis far from care. It points away from the respiratory complaints we spent this whole article cautioning about. Nobody should be carrying azithromycin to self-treat a cough or reaching for ciprofloxacin because their sinuses hurt. That’s the category where overdiagnosis already runs the show, and a kit there makes it worse, not better.

And we have to be candid about the risk, because pretending it away is how stewardship gets undermined. Just having antibiotics on hand is associated with using them more, and using them less appropriately, even among travelers who know better.⁸ That finding doesn’t kill the standby model. It sets the bar for it: the only version that survives that data is one where a clinician scoped the drug, the indication, and the “do not use this for X” before the patient ever walked out with it.

That discipline has a name. We call it appropriate medical preparation: the right drug, for the right indication, with a clear plan, and a clinician making the call. We’re a family team of physicians, PAs, and pharmacists, and it’s the standard we hold the JaseCase to. The kit removes the access barrier for the moment one is genuinely needed. It does not move the decision, and it is not a replacement for primary care, it’s for the times primary care isn’t reachable. If you’ve got patients who travel hard, live remote, or have a recurrent condition you’ve already worked up, you can point them to us at jase.com. And we’ll keep publishing where we draw these lines, and where we refuse to, so the framework is out in the open for the people who’d have to defend it.

The bottom line

Here’s where it all nets out. Most of the time, the patient in front of you who is certain they need an antibiotic doesn’t. The win isn’t a faster diagnosis or a stronger drug. It’s the right action at the right moment, and that action is usually one of three things (none of which is a rushed prescription): reassurance and a clear picture of what normal looks like, or symptom care plus a return plan, or “this one’s serious, let’s get you seen now.” Only in a narrow, pre-worked-out set of cases does it become “you already have what you need, and a clinician already decided when to use it.”

That’s what “having what you need” really means in the gray space. Not a pill for every bug. The judgment to tell the difference, the patience to wait when waiting is right, and the preparation so access is never the thing standing between a patient and the care they genuinely need. Get those three right and you’re practicing at the top of your training, even, and especially, on the days the answer won’t come clean.

That’s the discipline behind how we build, and how we’d ask anyone to build, a standby kit worth trusting.

Sources

1. Nicolle LE, et al. IDSA 2019 Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria. Clin Infect Dis. 2019;68(10):e83-e110. Screening and treatment recommended only in pregnancy and before invasive urologic procedures; treating ASB otherwise drives inappropriate use. https://www.idsociety.org/practice-guideline/asymptomatic-bacteriuria/
2. Brown BD, Hood Watson KL. Cellulitis. StatPearls. Uncomplicated cellulitis improves within 24 to 48 hours of therapy; pain out of proportion to exam, rapid progression over hours, and systemic toxicity raise concern for necrotizing infection and warrant emergent evaluation. https://www.ncbi.nlm.nih.gov/books/NBK549770/
3. Choby BA. Diagnosis and Treatment of Streptococcal Pharyngitis. Am Fam Physician. 2009;79(5):383-390. Modified Centor: score 0-1 needs neither testing nor antibiotics; 2-3 warrants RADT or culture with treatment only if positive. https://www.aafp.org/pubs/afp/issues/2009/0301/p383.html
4. Harris AM, Hicks LA, Qaseem A. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the ACP and the CDC. Ann Intern Med. 2016;164(6):425-434. No antibiotics for uncomplicated bronchitis unless pneumonia is suspected; antibiotics in rhinosinusitis only for severe or persistent (beyond ~10 days) symptoms; none for cold or influenza. https://www.acpjournals.org/doi/10.7326/M15-1840
5. Spurling GKP, Del Mar CB, Dooley L, et al. Delayed antibiotic prescriptions for respiratory infections. Cochrane Database of Systematic Reviews. 2017;9:CD004417. 11 trials, 3,555 participants; delayed prescribing reduces antibiotic use versus immediate, with no significant difference in complications and comparable patient satisfaction. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004417.pub5/full
6. Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis. BMJ. 2021. 9 RCTs plus 4 observational studies, 55,682 patients; no difference in symptom severity delayed versus immediate, safe and effective for most including higher-risk subgroups, with slightly higher symptom severity only in children under 5. https://pmc.ncbi.nlm.nih.gov/articles/PMC8080136/
7. The Safety of Delayed Versus Immediate Antibiotic Prescribing for Upper Respiratory Tract Infections. Clin Infect Dis. 2021;73(2):e394-e401. 1.82 million patients; delayed prescribing associated with higher infection-related hospital admission (adjusted HR 1.52), with delayed prescriptions not well targeted to lower-risk patients, which underscores the need for case selection and clear return precautions. https://academic.oup.com/cid/article/73/2/e394/5864470
8. Kantele A, et al. Stand-by antibiotics encourage unwarranted use of antibiotics for travelers’ diarrhea: A prospective study. Travel Medicine and Infectious Disease. 2018;23:7-13. 316 travelers; carrying standby antibiotics raised antibiotic use to 34% versus 11% in non-carriers, with the excess driven by mild-to-moderate illness. https://pubmed.ncbi.nlm.nih.gov/29894796/